Eran Elinav
Principal Investigator
Weizmann Institute of Science
Prof. Eran Elinav, M.D., Ph.D. is a professor of immunology at the Department of Immunology, Weizmann Institute of Science, and since 2019 the director of the cancer-microbiome division, at the Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. Dr. Elinav has published more than 200 publications in leading peer-reviewed journals, focusing on host-microbiome interactions, and was awarded multiple prestigious international awards for his discoveries. He is a senior fellow at the Canadian Institute For Advanced Research (CIFAR), an elected member, European Molecular Biology Organization (EMBO) and an international scholar at the Howard Hughes Medical Institute (HHMI) and the Bill & Melinda Gates Foundation.
abstract
Host Microbiome Interactions in Health and Disease
The mammalian intestine contains trillions of microbes, a community that is dominated by members of the domain Bacteria but also includes members of Archaea, Eukarya, and viruses. The vast repertoire of this microbiome functions in ways that benefit the host. The mucosal immune system co-evolves with the microbiota beginning at birth, acquiring the capacity to tolerate components of the community while maintaining the capacity to respond to invading pathogens. The gut microbiota is shaped and regulated by multiple factors including our genomic composition, the local intestinal niche and multiple environmental factors including our nutritional repertoire and bio-geographical location. Moreover, it has been recently highlighted that dysregulation of these genetic or environmental factors leads to aberrant host-microbiome interactions, ultimately predisposing to pathologies ranging from chronic inflammation, obesity, the metabolic syndrome and even cancer. We have identified various possible mechanisms participating in the reciprocal regulation between the host and the intestinal microbial ecosystem, and demonstrate that disruption of these factors, in mice and humans, lead to dysbiosis and susceptibility to common multi-factorial disease. Understanding the molecular basis of host-microbiome interactions may lead to development of new microbiome-targeting treatments.